Molecular profiling reveals differences between primary and recurrent ovarian cancers

February 10, 2012 in Cancer

There is a need to analyze tumor specimens at the time of ovarian cancer recurrence, according to a new study published in Molecular Cancer Therapeutics. Researchers used a diagnostic technology called molecular profiling to examine the differences in the molecular characteristics of primary and recurrent ovarian tumors and found significant changes for some biomarkers. This is the first study that examined potential differences in a broad biomarker panel in patient-matched primary versus recurrent ovarian cancers and underscores the importance of analyzing the most current tumor tissue in order to make the most informed decisions about treatment for recurrence.

Ovarian cancer is the most deadly of gynecological cancers, and is the fifth leading cause of cancer-related death among women in the United States. Treatment for recurrent often follows a trial and error approach in spite of molecular profiling technologies available to inform treatment selection. Profiling technologies may be utilized at the time of ovarian , but the tumor specimens that are analyzed are most often those obtained at initial diagnosis. This profiling of the primary tumor does not take into account changes that occur in recurrent tumors, which may have enabled their survival after chemotherapy treatment.

Lead author Deb Zajchowski, Ph.D., Scientific Director of The Clearity Foundation says, "These results highlight additional challenges for the treatment of recurrent ovarian cancer. The study helps us appreciate the degree to which tumor characteristics that may be useful for making may change over the course of this disease."

Dr. Zajchowski, Clearity Scientific Advisor Beth Y. Karlan, M.D. of Cedar-Sinai's Women's Cancer Program and colleagues analyzed data already collected by The Clearity Foundation and the Diane Barton Database. They employed 18 different immunohistochemical analyses at Clinical Laboratory Improvement Amendments (CLIA)-certified labs to analyze 43 matched tumor specimens from 19 advanced stage carcinoma patients for a panel of proteins that are correlated with drug response, discovering that expression levels of five different biomarkers were discordant in more than 40% of the matched tumor samples. These differences may be sufficiently large as to impact selection of therapy.

"These results demonstrate the dynamic genetic changes in ovarian cancers between diagnosis and recurrence. While the expression of these and other candidate response biomarkers should be evaluated in larger studies to better understand the clinical utility of profiling recurrent tumor specimens, this report highlights our urgent need to individualize our treatment approaches in order to improve ovarian cancer survival," says Dr. Karlan, Director of the Cedars-Sinai Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute and a renowned expert in the field of gynecologic oncology.

Ovarian cancers are very different from patient to patient, which means they are likely to respond differently to FDA-approved and investigational drugs. By identifying the alterations in each tumor's information pathways, molecular profiling enables the individualization of a patient's treatment by matching those tumor alterations with one or more drugs. The Clearity Foundation has developed a process for generating this personalized diagnostic information using commercially-available molecular profiling technologies and then analyzing the results using its Diane Barton Database.

Provided by The Clearity Foundation

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts
  • Potential Breakthrough in Seizure Control
    createdMay 26, 2012
  • Popping/Cracked sternum.
    createdMay 25, 2012
  • Which Mental Illness Encompasses This Problem?
    createdMay 25, 2012
  • A question about drug tolerance
    createdMay 23, 2012
  • Poor nutrition leading to overeating?
    createdMay 23, 2012
  • Math and dyslexia?
    createdMay 21, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Skp2 activates cancer-promoting, glucose-processing Akt

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

Cancer created May 25, 2012 | popularity not rated yet | comments 0 | with audio podcast

Pancreatectomy OK without downstaging from therapy

(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published ...

Cancer created May 25, 2012 | popularity not rated yet | comments 0

Common therapies for basal cell carcinoma offer similar survival

(HealthDay) -- For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival, according to a review published ...

Cancer created May 25, 2012 | popularity not rated yet | comments 0

Cancer may require simpler genetic mutations than previously thought

Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...

Cancer created May 25, 2012 | popularity not rated yet | comments 0 | with audio podcast

New prostate cancer screening guidelines face a tough sell, study suggests

(Medical Xpress) -- Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter ...

Cancer created May 25, 2012 | popularity not rated yet | comments 2


T cells 'hunt' parasites like animal predators seek prey, study shows

By pairing an intimate knowledge of immune-system function with a deep understanding of statistical physics, a cross-disciplinary team at the University of Pennsylvania has arrived at a surprising finding: T cells use a movement ...

Same gene that stunts infants' growth also makes them grow too big: research

UCLA geneticists have identified the mutation responsible for IMAGe* syndrome, a rare disorder that stunts infants' growth. The twist? The mutation occurs on the same gene that causes Beckwith-Wiedemann syndrome, which makes ...

Almost half of new vets seek disability

(AP) -- America's newest veterans are filing for disability benefits at a historic rate, claiming to be the most medically and mentally troubled generation of former troops the nation has ever seen.

Color-changing contact lenses to help diabetics (w/ Video)

For the millions of Americans with diabetes, the inconvenient and often painful method of testing blood sugar levels is a way of life. But research and innovative product design by scientists at The University of Akron may ...

Missouri opts for untested drug for executions

(AP) -- The same anesthetic that caused the overdose death of pop star Michael Jackson is now the drug of choice for executions in Missouri, causing a stir among critics who question how the state can guarantee ...

Thioridazine kills cancer stem cells in human while avoiding toxic side-effects of conventional cancer treatments

A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments.